What is OmniTier?
OmniTier provides fast, accurate, and scalable end-to-end genomic analysis solutions via user-friendly standalone appliances. Their technology empowers researchers, clinicians, and bioinformaticians to implement custom methodologies securely and cost-effectively. The company targets a broad clientele, including pharmaceutical firms, clinical diagnosis providers, academic researchers, and genomics data providers, with a specific focus on improving diagnostic rates for rare genetic diseases and advancing affordable precision medicine.
How much funding has OmniTier raised?
OmniTier has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in OmniTier
PPP
Public-Private Partnership
What's next for OmniTier?
With its large-scale late-stage funding context and a recent strategic investment, OmniTier is positioned for significant growth and market expansion. The capital infusion is expected to accelerate the development and deployment of its genomic analysis platforms, potentially leading to broader adoption in clinical settings and research institutions. This strategic backing suggests confidence from investors in OmniTier's ability to deliver on its promise of affordable precision medicine and improve global healthcare outcomes.
See full OmniTier company page
